ARK Israel Innovative Technology ETF (IZRL) is a publicly traded the market company. As of May 21, 2026, IZRL trades at $28.44 with a market cap of $0 and a P/E ratio of 0.00. IZRL moved +0.00% today. Year to date, IZRL is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces IZRL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Teva’s 44-Week Trial Shows Up to 58% Remission, Shares Rally 2.85%: RELIEVE UCCD extension study ran 44 weeks demonstrating 58% clinical remission in ulcerative colitis at 900 mg and 47% at 450 mg, with 55% and 41% endoscopic responses in Crohn’s patients. Teva shares rose 2.85% premarket as Goldman Sachs, Barclays and Scotiabank lifted price targets to $45, $38 and $40.
| Metric | Value |
|---|---|
| Price | $28.44 |
| Market Cap | $0 |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $0.00 |
| 52-Week Low | $0.00 |
| Volume | 122.61K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
IZRL analyst coverage data. Average price target: $0.00.